Related Experiment Video
Updated: Aug 16, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased
Peter A Senior1, Breay W Paty, Sandra M Cockfield
1Clinical Islet Transplant Program, University of Alberta, Edmonton, Alberta, Canada. petersenior@ualberta.ca
Abstract:
Sirolimus is a potent immunosuppressant, which may permit the avoidance of nephrotoxic calcineurin inhibitors (CNI). However, cases of proteinuria associated with sirolimus have been reported following renal transplantation. Here, we report three cases of proteinuria (1, 2 and 7 g/day) developing during therapy with sirolimus plus low-dose tacrolimus following clinical islet transplantation (CIT) in type I diabetic subjects. The proteinuria resolved after discontinuation of sirolimus, substituted by mycophenolate mofetil (MMF) combined with an increased dose of tacrolimus. A renal biopsy in one case indicated only the presence of diabetic glomerulopathy. Five other CIT recipients developed microalbuminuria while on sirolimus which all resolved after switching to tacrolimus and MMF. The resolution of proteinuria from the native kidneys of CIT recipients after the discontinuation sirolimus suggests that, at least in some individuals, sirolimus itself may have adverse renal effects. Sirolimus should be used cautiously with close monitoring for proteinuria or renal dysfunction.
Related Concept Videos
Type I Diabetes III: Clinical Manifestations
Kidney Transplant II: Surgical Procedure
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Acute Kidney Injury III: Clinical Manifestations
Kidney Transplant III: Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management